Glucagon
Brand Names: Baqsimi, Glucagon Emergency
Methodology & AI Transparency ⓘ
Glucagon Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage baqsimi:™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes.
- 2 Real-world patient consensus: Zero-PHI community consensus: 76% favorable across 9 logged regimens (Baqsimi, Glucagon Emergency).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $94.41 wholesale mail-order against $231.30 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Glucagon: nausea (11.9%), headache (10.5%), vomiting (5.5%).
Ask our AI Specialists anything about Glucagon
Glucagon Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage baqsimi:™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. BAQSIMI ® is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. ( 1 )
12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.
Following administration (1 mg/mL Injection, Powder, Lyophilized, for Solution), Glucagon achieves Complete (~100%) parenteral systemic delivery for Glucagon (1 mg/mL Injection, Powder, Lyophilized, for Solution) bioavailability and peak plasma tmax within 15 minutes (glucagon) onset, governed by a 35 minutes terminal elimination (Glucagon SPL) terminal half-life through systemic clearance of glucagon integrates hepatic phase ii conjugation with renal filtration.
Before initiating Glucagon at 1 mg/mL Injection, Powder, Lyophilized, for Solution, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to glucagon (ndc 85766-065); severe baseline organ impairment where glucagon accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (11.9% of reports), headache (10.5% of reports), nasopharyngitis (8.6% of reports).
Glucagon may displace or alter hepatic clearance of warfarin; check baseline and post-titration INR.
Reconcile eGFR-adjusted medications before escalating Glucagon in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Glucagon (NDC 85766-065)
- Severe baseline organ impairment where Glucagon accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (9 Reports)
Glucagon Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glucagon)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Glucagon-like peptide-1 receptor agonists and: What a 14,972-Participant Study Found The present meta-analysis does not suggest any increase in the risk of pancreatitis with the use of GLP-1RA. Diabetes research and clinical practice • 2014-02-15 • Meta-Analysis | N = 14,972 | 99/100 | PMID 24485345 ↗ |
| New Insights on Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the: What a 12,300-Participant Study Found GLP-1RAs triggered more gastrointestinal side effects than placebo, with no in-between difference. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2023-03-15 • Meta-Analysis | N = 12,300 | 99/100 | PMID 36579723 ↗ |
| New Insights on Heart and blood vessel and Kidney Outcomes and Mortality With Long-Acting: What a 71,351-Participant Study Found As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D. Diabetes care • 2025-05-01 • Meta-Analysis | N = 71,351 | 99/100 | PMID 40156846 ↗ |
| New Insights on Effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on: What a 430-Participant Study Found Observational studies suggest a decrease in alcohol-related events, but RCTs have effects on alcohol consumption and craving that remain non-significant. Addiction science & clinical practice • 2025-12-05 • Meta-Analysis | N = 430 | 97/100 | PMID 41350683 ↗ |
Glucagon Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $284.8288/unit (~$8544.86/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $94.41 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $231.30 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $108.57 / mo | View logs ↓ |
Glucagon Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glucagon RxNorm Concept ID | 2180666 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $284.8288 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $231.30 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $94.41 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 76.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Glucagon Patient Community, Cohort Filters & Dosage Logs
Cross-verified Glucagon (antihypoglycemic agent) monograph synthesizing RxNorm 2180666, openFDA FAERS signals, and $94.41–$231.30 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Glucagon community threads and patient logs by age, biological sex, dosage, and treatment duration.